Philip J. Vickers - 04 May 2022 Form 4/A - Amendment Insider Report for Revance Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 04 May 2022
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 13 May 2022, 18:13:27 UTC
Original report date: 06 May 2022
Prior SEC filing: 08 Jul 2021
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Dwight Moxie, Attorney-in-Fact

Key filing fact

Philip J. Vickers filed Form 4/A - Amendment for Revance Therapeutics, Inc. on 13 May 2022.

Key facts

This page summarizes Philip J. Vickers's Form 4/A - Amendment filing for Revance Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 May 2022, 18:13.

Change

Previous filing in this sequence was filed on 08 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVNC transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +10,756
Change %
Price: $0.000000
Shares after: 10,756
Date: 04 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,756
Exercise price: $18.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Dr. Vickers' Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

SEC remarks

The original Form 4, filed on May 6, 2022, inadvertently listed the incorrect number of options granted to the Reporting Person on May 4, 2022 due to an administrative error. This Form 4/A is being filed to correct the number of shares underlying the stock option originally reported.